0.05  0 (0%)		04-04 16:00
Open: 0.064 High: 0.0643 Volume: 46,746,028		Pre. Close: 0.05 Low: 0.05 Market Cap: 18(M)

Short term
Mid term
Targets	6-month :	0.06	1-year :	0.07
Resists	First :	0.05	Second :	0.06
Pivot price	0
Supports	First :	0.05	Second :	0.04
MAs	MA(5) :	0	MA(20) :	0
	MA(100) :	0	MA(250) :	0
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	0	D(3) :	0
RSI	RSI(14): 0
52-week	High :	0.06	Low :	0.05

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ AMRS ] has closed Bollinger Bands are 0% narrower than normal.

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.

Fri, 12 Apr 2024
AMYRIS INITIATES STRATEGIC TRANSFORMATION PROGRAM AND SECURES FUNDING - The Globe and Mail

Fri, 11 Aug 2023
AMRS Stock Surges 152% as Amyris Files for Bankruptcy - InvestorPlace

Thu, 10 Aug 2023
Amyris Files for Chapter 11 Bankruptcy - WWD

Thu, 10 Aug 2023
Amyris: Shareholders Likely To Be Wiped Out In Chapter 11 - Sell (NASDAQ:AMRS) - Seeking Alpha

Thu, 10 Aug 2023
Why Is Amyris (AMRS) Stock Down 67% Today? - InvestorPlace

Thu, 10 Aug 2023
Biotech Company Amyris Files for Bankruptcy - Investopedia

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Basic Materials
Industry: Chemicals - Specialty
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.